Production & Sales

EC grants marketing authorisation for IntraBio’s Aqneursa

The European Commission (EC) has granted marketing authorisation for IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms of Niemann-Pick disease type C (NPC).

SERB signs agreement to acquire Idefirix rights for $133.6m

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for a total of €115m ($133.6m).

GSK and SBP Group team up to advance bepirovirsen launch in China

GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.

Novo Nordisk to launch Ozempic for type 2 diabetes in US

Novo Nordisk is set to launch Ozempic, its oral glucagon-like peptide-1 (GLP-1) receptor agonist pill for adults with type 2 diabetes, in the US.

Regeneron Q1 2026 net income falls 10% to $727m

Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting Principles] net income of $727m for the first quarter of 2026 (Q1 2026), down 10% from $809m in Q1 2025.

Cumberland to sell drug portfolio to Apotex for $100m

Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash.

Aligos and Xiamen Amoytop sign deal for HBV therapy

Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.

Idorsia and Pharmalink sign agreement to distribute Quviviq

Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in Kuwait, Oman, Qatar, Bahrain, and the United Arab Emirates (UAE).

Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m

Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m).